Executive leadership at Incannex Healthcare.
Board of directors at Incannex Healthcare.
Research analysts covering Incannex Healthcare.
Recent press releases and 8-K filings for IXHL.
Incannex Healthcare reports strong 2025 progress and outlines well-funded 2026 outlook
IXHL
Guidance Update
Share Buyback
New Projects/Investments
- Incannex Healthcare Inc. enters 2026 with over $70 million in cash on hand, providing an operating runway well into 2027.
- In 2025, the company achieved two positive Phase 2 clinical readouts across distinct CNS programs and received FDA Fast Track Designation for its lead obstructive sleep apnea candidate, IHL-42X.
- The company strengthened its balance sheet by eliminating all outstanding Series A warrants and authorizing a $20 million share repurchase program.
Jan 14, 2026, 12:30 PM
Incannex Healthcare Inc. Receives FDA Fast Track Designation for IHL-42X
IXHL
Product Launch
New Projects/Investments
- Incannex Healthcare Inc. (IXHL) announced on December 3, 2025, that its oral fixed-dose combination product candidate, IHL-42X, received U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of obstructive sleep apnea (OSA).
- The designation was supported by promising safety, efficacy, and pharmacokinetic results from three clinical trials, including a successful Phase 2 "RePOSA" study which demonstrated statistically significant reductions in Apnea-Hypopnea Index (AHI).
- Fast Track designation provides benefits such as more frequent FDA interactions, eligibility for rolling review of a New Drug Application (NDA), and potential access to Accelerated Approval and Priority Review.
- Management views this as a significant regulatory milestone that validates the potential of IHL-42X to address the unmet medical need for an oral pharmacotherapy for OSA and provides an expedited regulatory pathway.
Dec 3, 2025, 1:00 PM
Incannex Healthcare Inc. Granted Nasdaq Extension for Bid Price Compliance
IXHL
Delisting/Listing Issues
- Incannex Healthcare Inc. (IXHL) has received a 180-calendar-day extension from the Nasdaq Stock Market to regain compliance with the minimum bid price requirement.
- The company now has until April 20, 2026, to maintain a closing bid price of at least US$1.00 per share for a minimum of ten consecutive business days.
- Nasdaq granted the extension after determining that Incannex continues to meet all other continued listing criteria.
- Incannex has provided written notice of its intention to cure the deficiency, if necessary, through a reverse stock split.
Oct 22, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more